1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Jan 2026
Admin
News Article

FDA Clears MicuRx IND for MRX-5 to Enter Phase 2a Trial in M. abscessus Pulmonary Disease

MicuRx Pharmaceuticals, Inc. has received U.S. FDA clearance for its Investigational New Drug (IND) application for MRX-5, enabling initiation of a Phase 2a clinical trial in patients with Mycobacterium abscessus pulmonary disease.

The clearance marks a key step forward for a program targeting a serious and difficult-to-treat non-tuberculous mycobacterial (NTM) infection with limited effective therapies.

Why M. abscessus Pulmonary Disease Needs Better Treatments?

M. abscessus pulmonary disease is associated with:

High morbidity and progressive lung damage
Long, complex multi-drug treatment regimens
Poor tolerability and frequent adverse effects
Suboptimal clinical outcomes

There are currently few effective oral options and no reliably curative therapies.

About MRX-5

MRX-5 is a novel, oral antibacterial agent designed to target NTM infections.

Preclinical and early clinical data show that MRX-5:

Demonstrates potent activity against clinical isolates of M. abscessus
Remains active against strains resistant to standard-of-care therapies
Exhibits favorable pharmacokinetic properties
Shows an encouraging safety profile

In 2024, the FDA granted Orphan Drug Designation to MRX-5 for the treatment of NTM infections.

Phase 2a Trial Overview

The Phase 2a study will be:

Multicenter
Conducted in the United States
Enrolling adults with confirmed M. abscessus pulmonary disease

Primary objectives include evaluating:

Safety and tolerability
Preliminary efficacy

Results will guide subsequent development and later-stage trial design.

Company Perspective

Jerry (Zhiyue) Li, President of MicuRx, stated:

The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M. abscessus pulmonary disease. This approval allows us to advance MRX-5 into a Phase 2a clinical trial to assess its safety and efficacy.

Expanding MicuRx’s Anti-Infective Pipeline

The IND clearance strengthens MicuRx’s clinical pipeline focused on:

Drug-resistant bacterial infections
Antimicrobial resistance challenges
Hard-to-treat NTM diseases

MicuRx continues to leverage its expertise in medicinal chemistry and anti-infective drug development to address major global unmet medical needs.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!